Context Therapeutics Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022; filed August 11, 2022. Context is a clinical-stage biopharmaceutical company focused on therapies for women’s cancers. It reported no revenue and has not commercialized a product.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Research and development | $1.52 million | $1.33 million | $2.87 million | $1.77 million |
| General and administrative | $1.99 million | $0.60 million | $4.08 million | $1.01 million |
| Acquired in-process R&D | $0.50 million | $3.09 million | $0.50 million | $3.09 million |
| Net loss | $3.99 million | $5.03 million | $7.42 million | $5.92 million |
| Operating cash used | Not reported quarterly | Not reported quarterly | $6.63 million | $3.79 million |
- Q2 net loss improved 21% year over year, primarily because the prior-year period included $3.09 million of initial collaboration-related acquired in-process R&D expense. For the first half, net loss increased 25%, reflecting higher R&D and G&A spending.
- First-half R&D rose 62%, driven mainly by ONA-XR manufacturing and clinical-trial costs and increased personnel. G&A rose 306%, reflecting higher compensation, insurance, professional fees, and public-company costs.
- Cash and cash equivalents were $42.92 million at June 30, down from $49.64 million at December 31, 2021. Total liabilities were $3.05 million; the filing reports no current debt. Stockholders’ equity was $41.65 million and accumulated deficit was $36.68 million.
- First-half investing cash outflow was $0.04 million, mainly property and equipment purchases; financing cash outflow was $0.10 million, related to private-placement offering costs. There is no meaningful revenue margin to report.
Material changes, outlook, and risks
- Management estimated that available cash would fund operations into the fourth quarter of 2023. The financial-statement note separately states cash was expected to fund projected operations for at least 12 months from issuance. Both estimates depend on assumptions and actual cash use may be faster.
- The company expects continued operating losses and rising R&D, G&A, and capital needs, and says it will need substantial additional capital. No credit facility or committed funding source was reported. Additional financing may dilute shareholders or require restrictive terms or relinquishment of rights.
- Clinical outlook: preliminary data from investigator-sponsored ONA-XR trials in endometrial and ovarian cancer and metastatic breast cancer was expected in Q4 2022; Phase 1b data in another breast cancer study was expected in mid-2023. The company expected to select a CLDN6 bispecific antibody candidate for IND-enabling studies in Q4 2022.
- In August 2022, after quarter-end, Menarini agreed to supply elacestrant at no cost for a planned Phase 1/2 combination study with ONA-XR. Context will sponsor, fund, and conduct the study; the agreement provides no development, regulatory, or sales milestone payments to Menarini.
- Integral Molecular may receive up to $54.8 million in development and regulatory milestones, up to $130.0 million in sales milestones, and royalties up to 12% under the CLDN6 agreement. Tyligand arrangements include potential $2.0 million and $3.0 million manufacturing scale-up payments and a 1% net-sales payment under specified terms.
- Key risks include clinical and regulatory uncertainty, reliance on third-party clinical and manufacturing providers, the need for further financing, potential trial delays or cost increases from COVID-19, and competition and intellectual-property risks. The company reported no material legal proceedings and no material changes to the risk factors in its 2021 Form 10-K.
Important facts for investors to verify
- Whether actual cash use and updated forecasts remain consistent with the stated Q4 2023 runway, and when additional financing may be required.
- Progress, enrollment, timing, and results of the ONA-XR studies and the CLDN6 candidate-selection and IND-enabling plans.
- Whether the Menarini combination study proceeds as planned and what costs Context incurs to sponsor and conduct it.
- Potential milestone, royalty, manufacturing, and warrant-related obligations or dilution; 5.86 million warrants were outstanding at June 30, 2022.
- Whether rising operating costs, trial timing, or external disruptions materially change the company’s development plans or financing needs.